Alterity Therapeutics (ATHE) Interest & Investment Income (2018 - 2019)
Alterity Therapeutics' (ATHE) quarterly Interest & Investment Income came in at $9655.5 in Q4 2019, down 79.72% year-on-year from $47609.3 in Q4 2018, and down 79.72% quarter-over-quarter from $47609.3 in Q4 2018.
Alterity Therapeutics (ATHE) Interest & Investment Income (2018 - 2019) Analysis & Trends
Alterity Therapeutics' Interest & Investment Income history runs 2 years deep, the most recent figure standing at $9655.5 for Q4 2019.
- On a quarterly basis, Interest & Investment Income fell 79.72% year-over-year to $9655.5 in Q4 2019; TTM through Dec 2019 was $465970.4, a N/A change from a year earlier, with the FY2025 full-year figure at $285819.6, up 61.58% from the prior year.
- Interest & Investment Income fell to $9655.5 in Q4 2019 per ATHE's latest filing, from $47609.3 in the prior quarter.
- Across five years, Interest & Investment Income topped out at $47609.3 in Q4 2018 and bottomed at $9655.5 in Q4 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 27.66 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 114.80 Mn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | -65.80 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 44.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 19.51 Mn |
| 10 | Alterity Therapeutics | 29.68 Bn | 29.68 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2019 | 9,655.51 |
| Dec 31, 2018 | 47,609.30 |